Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?

Journal of Diabetes Research

Volumn 2017, Issue , 2017, Pages

  Perez Matos, M C ^a   Morales Alvarez, M C ^a,b   Mendivil, C O ^a  

^a UNIVERSIDAD DE LOS ANDES   (Colombia)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HEMOGLOBIN A1C; HYPOCHOLESTEROLEMIC AGENT; INSULIN; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SPHINGOLIPID; THIOCTIC ACID; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

CARDIOVASCULAR RISK; CELL MEMBRANE; CHOLESTEROL SYNTHESIS; CORRELATIONAL STUDY; DIABETES CONTROL; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DYSLIPIDEMIA; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; NERVE CELL; NERVE CONDUCTION VELOCITY; NONHUMAN; OUTCOME ASSESSMENT; PHYSICAL CHEMISTRY; PROTEIN BINDING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DIABETIC NEUROPATHIES; DRUG EFFECTS; LIPID METABOLISM; METABOLISM;

ANIMALS; DIABETIC NEUROPATHIES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS;

EID: 85011545687     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2017/6943851     Document Type: Review

References (89)

1. M. Davies, S. Brophy, R. Williams, and A. Taylor, "The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes, " Diabetes Care, vol. 29, no. 7, pp. 1518-1522, 2006.
2. C.A. Abbott, R. A. Malik, E. R. E. Van Ross, J. Kulkarni, and A. J. M. Boulton, "Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K., " Diabetes Care, vol. 34, no. 10, pp. 2220-2224, 2011.
3. S. Tesfaye, A. J. M. Boulton, and A. H. Dickenson, "Mechanisms and management of diabetic painful distal symmetrical polyneuropathy, " Diabetes Care, vol. 36, no. 9, pp. 2456-2465, 2013.
4. S. Tesfaye, A. J. M. Boulton, P. J. Dyck et al., "Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments, " Diabetes Care, vol. 33, no. 10, pp. 2285-2293, 2010.
5. A. C. Themistocleous, J. D. Ramirez, J. Serra, and D. L. H. Bennett, "The clinical approach to small fiber neuropathy and painful channelopathy, " Practical Neurology, vol. 14, no. 6, pp. 368-379, 2014.
6. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulindependent diabetesmellitus, " New England Journal ofMedicine, vol. 329, no. 14, pp. 977-986, 1993.
7. C. L. Martin, J. Albers, W.H. Herman et al., "Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion, " Diabetes Care, vol. 29, no. 2, pp. 340-344, 2006.
8. J. W. Albers, W.H. Herman, R. Pop-Busui et al., "Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study, " Diabetes Care, vol. 33, no. 5, pp. 1090-1096, 2010.
9. Y. Ohkubo, H. Kishikawa, E. Araki et al., "Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study, " Diabetes Research and Clinical Practice, vol. 28, no. 2, pp. 103-117, 1995.
10. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., "Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial, " The Lancet, vol. 376, no. 9739, pp. 419-430, 2010.
11. W. Duckworth, C. Abraira, T. Moritz et al., "Glucose control and vascular complications in veterans with type 2 diabetes, " New England Journal of Medicine, vol. 360, no. 2, pp. 129-139, 2009.
12. R. Turner, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), " The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
13. ADVANCE Collaborative Group, A. Patel, S. MacMahon et al., "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, " The New England Journal of Medicine, vol. 358, pp. 2560-2572, 2008.
14. S. P. Marso, G. H. Daniels, K. B. Frandsen et al., "Liraglutide and cardiovascular outcomes in type 2 diabetes, " New England Journal of Medicine, vol. 375, no. 4, pp. 311-322, 2016.
15. B. Zinman, C. Wanner, J. M. Lachin et al., "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, " The New England Journal ofMedicine, vol. 373, no. 22, pp. 2117-2128, 2015.
16. G. Negi, A. Kumar, R. P. Joshi, and S. S. Sharma, "Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle, " Biochemical and Biophysical Research Communications, vol. 408, no. 1, pp. 1-5, 2011.
17. A. B. Oyenihi, A. O. Ayeleso, E. Mukwevho, and B. Masola, "Antioxidant strategies in themanagement of diabetic neuropathy, " BioMed Research International, vol. 2015, Article ID515042, 15 pages, 2015.
18. M. Greig, S. Tesfaye, D. Selvarajah, and I. D. Wilkinson, "Insights into the pathogenesis and treatment of painful diabetic neuropathy, " Handbook of Clinical Neurology, vol. 126, pp. 559-578, 2014.
19. N. Das Evcimen and G. L. King, "The role of protein kinase C activation and the vascular complications of diabetes, " Pharmacological Research, vol. 55, no. 6, pp. 498-510, 2007.
20. X.-L. Du, D. Edelstein, L. Rossetti et al., "Hyperglycemiainduced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12222-12226, 2000.
21. K. Sugimoto, M. Yasujima, and S. Yagihashi, "Role of advanced glycation end products in diabetic neuropathy, " Current Pharmaceutical Design, vol. 14, no. 10, pp. 953-961, 2008.
22. S. Tesfaye, N. Chaturvedi, S. E. M. Eaton et al., "Vascular risk factors and diabetic neuropathy, " The New England Journal of Medicine, vol. 352, no. 4, pp. 341-450, 2005.
23. T. D. Wiggin, K. A. Sullivan, R. Pop-Busui, A. Amato, A. A. F. Sima, and E. L. Feldman, "Elevated triglycerides correlate with progression of diabetic neuropathy, " Diabetes, vol. 58, no. 7, pp. 1634-1640, 2009.
24. A. G. Smith and J. R. Singleton, "Obesity and hyperlipidemia are risk factors for early diabetic neuropathy, " Journal of Diabetes and its Complications, vol. 27, no. 5, pp. 436-442, 2013.
25. B. Isomaa, M. Henricsson, P. Almgren, T. Tuomi, M.-R. Taskinen, and L. Groop, "The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes, " Diabetologia, vol. 44, no. 9, pp. 1148-1154, 2001.
26. A. Leventoglu and G. Morkavuk, "P225: small fiber neuropathy associated with hyperlipidemia: utility of cutaneous silent periods and autonomic tests, " Clinical Neurophysiology, vol. 125, supplement 1, p. S108, 2014.
27. B. Kim and E. L. Feldman, "Insulin resistance in the nervous system, " Trends in Endocrinology andMetabolism, vol. 23, no. 3, pp. 133-141, 2012.
28. C. W. Grote, J. K. Morris, J. M. Ryals, P. C. Geiger, and D. E. Wright, "Insulin receptor substrate 2 expression and involvement in neuronal insulin resistance in diabetic neuropathy, " Experimental Diabetes Research, vol. 2011, Article ID 212571, 12 pages, 2011.
29. V. Brussee, F. A. Cunningham, and D. W. Zochodne, "Direct insulin signalling of neurons reverses diabetic neuropathy, " Diabetes, vol. 53, no. 7, pp. 1824-1830, 2004.
30. C. W. Grote, A. L. Groover, J. M. Ryals, P. C. Geiger, E. L. Feldman, and D. E. Wright, "Peripheral nervous system insulin resistance in ob/ob mice, " Acta Neuropathologica Communications, vol. 1, no. 1, article 15, 2013.
31. M. Stecker and M. Stevenson, "Effects of insulin on peripheral nerves, " Journal of Diabetes and its Complications, vol. 30, no. 5, pp. 770-777, 2016.
32. B. Kim, L. L. McLean, S. S. Philip, and E. L. Feldman, "Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons, " Endocrinology, vol. 152, no. 10, pp. 3638-3647, 2011.
33. B. Draznin, "Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85: The two sides of a coin, " Diabetes, vol. 55, no. 8, pp. 2392-2397, 2006.
34. B. Sears and M. Perry, "The role of fatty acids in insulin resistance, " Lipids in Health and Disease, vol. 14, no. 1, article 121, 2015.
35. L. Han, L. Ji, J. Chang et al., "Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome, " Diabetology and Metabolic Syndrome, vol. 7, no. 1, article no. 14, 2015.
36. A. J. Garber, "Themetabolic syndrome, " Medical Clinics of North America, vol. 88, no. 4, pp. 837-846, 2004.
37. D. Dey, D. Basu, S. S. Roy, A. Bandyopadhyay, and S. Bhattacharya, "Involvement of novel PKC isoforms in FFA induced defects in insulin signaling, "Molecular and Cellular Endocrinology, vol. 246, no. 1-2, pp. 60-64, 2006.
38. T. C. Coste, A. Gerbi, P. Vague, J. M. Maixent, G. Pieroni, and D. Raccah, "Peripheral diabetic neuropathy and polyunsaturated fatty acid supplementations: natural sources or biotechnological needs?" Cellular and Molecular Biology, vol. 50, no. 7, pp. 845-853, 2004.
39. R. N. M. Weijers, "Membrane flexibility, free fatty acids, and the onset of vascular and neurological lesions in type 2 diabetes, " Journal of Diabetes and Metabolic Disorders, vol. 15, article 13, 2016.
40. M. K. Piya, P. G. McTernan, and S. Kumar, "Adipokine inflammation and insulin resistance: The role of glucose, lipids and endotoxin, " Journal of Endocrinology, vol. 216, no. 1, pp. T1-T15, 2013.
41. M. Roustit, J. Loader, C. Deusenbery, D. Baltzis, and A. Veves, "Endothelial dysfunction as a link between cardiovascular risk factors and peripheral neuropathy in diabetes, " The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 9, pp. 3401-3408, 2016.
42. P. O. O. Julu, "Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetic rats, " Journal of Diabetic Complications, vol. 2, no. 4, pp. 185-188, 1988.
43. H. Keen, J. Payan, J. Allawi et al., "Treatment of diabetic neuropathy with-linolenic acid, " Diabetes Care, vol. 16, no. 1, pp. 8-15, 1993.
44. D. Manzella, M. Barbieri, M. R. Rizzo et al., "Role of free fatty acids on cardiac autonomic nervous systemin noninsulindependent diabetic patients: effects of metabolic control, " Journal of Clinical Endocrinology andMetabolism, vol. 86, no. 6, pp. 2769-2774, 2001.
45. A. M. Vincent, J. L. Edwards, L. L. McLean et al., "Mitochondrial biogenesis and fission in axons in cell culture and animalmodels of diabetic neuropathy, " Acta Neuropathologica, vol. 120, no. 4, pp. 477-489, 2010.
46. A. Viader, Y. Sasaki, S. Kim et al., "Aberrant schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy, " Neuron, vol. 77, no. 5, pp. 886-898, 2013.
47. M. J. McManus, M. P. Murphy, and J. L. Franklin, "Mitochondria-derived reactive oxygen species mediate caspasedependent and-independent neuronal deaths, " Molecular and Cellular Neuroscience, vol. 63, pp. 13-23, 2014.
48. S. Boudina, S. Sena, H. Theobald et al., "Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins, " Diabetes, vol. 56, no. 10, pp. 2457-2466, 2007.
49. D. E. Kelley, J. He, E. V. Menshikova, and V. B. Ritov, "Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes, " Diabetes, vol. 51, no. 10, pp. 2944-2950, 2002.
50. M. E. Patti, A. J. Butte, S. Crunkhorn et al., "Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8466-8471, 2003.
51. E. Akude, E. Zherebitskaya, S. K. R. Chowdhury, D. R. Smith, R. T. Dobrowsky, and P. Fernyhough, "Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats, " Diabetes, vol. 60, no. 1, pp. 288-297, 2011.
52. D. Penzo, C. Tagliapietra, R. Colonna, V. Petronilli, and P. Bernardi, "Effects of fatty acids on mitochondria: implications for cell death, " Biochimica et Biophysica Acta-Bioenergetics, vol. 1555, no. 1-3, pp. 160-165, 2002.
53. E. Rial, L. Rodŕiguez-Śanchez, E. Gallardo-Vara, P. Zaragoza, E. Moyano, and M. M. Gonźalez-Barroso, "Lipotoxicity, fatty acid uncoupling and mitochondrial carrier function, " Biochimica et Biophysica Acta-Bioenergetics, vol. 1797, no. 6-7, pp. 800-806, 2010.
54. L. Wojtczak and M. R. Wieckowski, "The mechanisms of fatty acid-induced proton permeability of the inner mitochondrial membrane, " Journal of Bioenergetics and Biomembranes, vol. 31, no. 5, pp. 447-455, 1999.
55. L. M. Hinder, C. Figueroa-Romero, C. Pacut et al., "Longchain acyl coenzyme a synthetase 1 overexpression in primary cultured schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction, " Antioxidants and Redox Signaling, vol. 21, no. 4, pp. 588-600, 2014.
56. S. K. Roy Chowdhury, E. Zherebitskaya, D. R. Smith et al., "Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment, " Diabetes, vol. 59, no. 4, pp. 1082-1091, 2010.
57. L. M. Hinder, A. Vivekanandan-Giri, L. L. McLean, S. Pennathur, and E. L. Feldman, "Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes, " Journal of Endocrinology, vol. 216, no. 1, pp. 1-11, 2013.
58. O. J. Freeman, R. D. Unwin, A. W. Dowsey et al., "Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy, " Diabetes, vol. 65, no. 1, pp. 228-238, 2016.
59. J. N. Feige and J. Auwerx, "Transcriptional coregulators in the control of energy homeostasis, " Trends in Cell Biology, vol. 17, no. 6, pp. 292-301, 2007.
60. Z. Wu, P. Puigserver, U. Andersson et al., "Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1, " Cell, vol. 98, no. 1, pp. 115-124, 1999.
61. T. R. Koves, P. Li, J. An et al., "Peroxisome proliferator-Activated receptor-co-Activator 1-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency, " Journal of Biological Chemistry, vol. 280, no. 39, pp. 33588-33598, 2005.
62. V. K. Mootha, C. M. Lindgren, K.-F. Eriksson et al., "PGC-1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, " Nature Genetics, vol. 34, no. 3, pp. 267-273, 2003.
63. S. K. Roy Chowdhury, D. R. Smith, A. Saleh et al., "Impaired adenosine monophosphate-Activated protein kinase signaling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes, " Brain, vol. 135, no. 6, pp. 1751-1766, 2012.
64. T. Shibata, S. Takeuchi, S. Yokota, K. Kakimoto, F. Yonemori, and K. Wakitani, "Effects of peroxisome proliferator-Activated receptor-And- agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats, " British Journal of Pharmacology, vol. 130, no. 3, pp. 495-504, 2000.
65. I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov et al., "High-fat diet-induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition, " Diabetes, vol. 56, no. 10, pp. 2598-2608, 2007.
66. O. T. Njajou, A. M. Kanaya, P. Holvoet et al., "Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the health, aging and body composition study, " Diabetes/Metabolism Research and Reviews, vol. 25, no. 8, pp. 733-739, 2009.
67. A. M. Vincent, J. M. Hayes, L. L. McLean, A. Vivekanandan-Giri, S. Pennathur, and E. L. Feldman, "Dyslipidemia-induced neuropathy in mice: The role of oxLDL/LOX-1, " Diabetes, vol. 58, no. 10, pp. 2376-2385, 2009.
68. J. Duan and A. H. Merrill, "1-deoxysphingolipids encountered exogenously and made de novo: dangerous mysteries inside an enigma, " Journal of Biological Chemistry, vol. 290, no. 25, pp. 15380-15389, 2015.
69. R. Pralhada Rao, N. Vaidyanathan, M. Rengasamy, A. Mammen Oommen, N. Somaiya, and M. R. Jagannath, "Sphingolipid metabolic pathway: Anoverviewofmajor roles played inhuman diseases, " Journal of Lipids, vol. 2013, Article ID 178910, 12 pages, 2013.
70. R. Kramer, J. Bielawski, E. Kistner-Griffin et al., "Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy, " FASEB Journal, vol. 29, no. 11, pp. 4461-4472, 2015.
71. N. Wei, J. Pan, R. Pop-Busui et al., "Altered sphingoid base profiles in type 1 compared to type 2 diabetes, " Lipids in Health and Disease, vol. 13, no. 1, article no. 161, 2014.
72. M. Bertea, M. F. Rütti, A. Othman et al., "Deoxysphingoid bases as plasma markers in diabetes mellitus, " Lipids in Health and Disease, vol. 9, article no. 84, 2010.
73. M. F. Dohrn, A. Othman, S. K. Hirshman et al., "Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: A susceptibility to neuropathy?" European Journal of Neurology, vol. 22, no. 5, pp. 806-e55, 2015.
74. S. M. Hammad, N. L. Baker, J. M. El Abiad et al., "Increased plasma levels of select deoxy-ceramide and ceramide species are associated with increased odds of diabetic neuropathy in type 1 diabetes: A pilot study, " NeuroMolecular Medicine, 2016.
75. A. Othman, R. Bianchi, I. Alecu et al., "Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats, " Diabetes, vol. 64, no. 3, pp. 1035-1045, 2015.
76. A. Othman, R. Benghozi, I. Alecu et al., "Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?" Journal of Clinical Lipidology, vol. 9, no. 4, pp. 568-575, 2015.
77. T.M. E. Davis, B. B. Yeap, W. A. Davis, andD.G. Bruce, "Lipidlowering therapy and peripheral sensory neuropathy in type 2 diabetes: The Fremantle Diabetes Study, " Diabetologia, vol. 51, no. 4, pp. 562-566, 2008.
78. K. Rajamani, P. G. Colman, L. P. Li et al., "Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial, " The Lancet, vol. 373, no. 9677, pp. 1780-1788, 2009.
79. Y. R. Cho, J. H. Lim, M. Y. Kim et al., "Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice, " PLoS ONE, vol. 9, no. 1, Article ID 0083204, 2014.
80. D.-J. Lou, Q.-Q. Zhu, X.-W. Si et al., "Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-Alcoholic fatty liver disease, " Journal of Diabetes and Its Complications, vol. 28, no. 5, pp. 711-714, 2014.
81. J. Li, F. R. Li, D. Wei et al., "Endogenous-3 polyunsaturated fatty acid production confers resistance to obesity, dyslipidemia, and diabetes in mice, " Molecular Endocrinology, vol. 28, no. 8, pp. 1316-1328, 2014.
82. T. C. Coste, A. Gerbi, P. Vague, G. Pieroni, and D. Raccah, "Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy, " Diabetes, vol. 52, no. 10, pp. 2578-2585, 2003.
83. A. Gerbi, J.-M. Maixent, J.-L. Ansaldi et al., "Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats, " Journal of Nutrition, vol. 129, no. 1, pp. 207-213, 1999.
84. F. R. Danesh, R. L. Anel, L. Zeng, J. Lomasney, A. Sahai, and Y. S. Kanwar, "Immunomodulatory effects of HMG-CoA reductase inhibitors, " Archivum Immunologiae et Therapiae Experimentalis, vol. 51, no. 3, pp. 139-148, 2003.
85. N. Cameron, M. Cotter, M. Inkster, and M. Nangle, "Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models, " Diabetes Research and Clinical Practice, vol. 61, supplement 1, pp. S35-S39, 2003.
86. G. Villegas-Rivera, L. M. Roḿan-Pintos, E. G. Cardona-Muñoz et al., "Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: A randomized, doubleblind, placebo-controlled clinical trial, " OxidativeMedicine and Cellular Longevity, vol. 2015, Article ID 756294, 10 pages, 2015.
87. L. Packer, K. Kraemer, and G. Rimbach, "Molecular aspects of lipoic acid in the prevention of diabetes complications, " Nutrition, vol. 17, no. 10, pp. 888-895, 2001.
88. T. Han, J. Bai, W. Liu, and Y. Hu, "A systematic review andmetaanalysis of-lipoic acid in the treatment of diabetic peripheral neuropathy, " European Journal of Endocrinology, vol. 167, no. 4, pp. 465-471, 2012.
89. A. Hovaguimian and C. H. Gibbons, "Diagnosis and treatment of pain in small-fiber neuropathy, " Current Pain and Headache Reports, vol. 15, no. 3, pp. 193-200, 2011.